The “United States Diabetes Care Devices Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Diabetes Care Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market categories - Glucose Monitoring and Insulin Delivery
The United States Diabetes Care Devices Market report provides key information and data on:
- Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market categories. Data is provided from 2018 to 2033.
- 2023 company share and distribution share data for Diabetes Care Devices Market.
- Global corporate-level profiles of key companies operating within the United States Diabetes Care Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Scope
United States Diabetes Care Devices is segmented as follows:
- Glucose Monitoring
- Insulin Delivery
Reasons to Buy
The United States Diabetes Care Devices Market report helps you to develop:
- Business strategies by identifying the key market segments poised for strong growth in the future.
- Market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- Understand the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Diabetes Care Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report
2.2 Diabetes Care Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Diabetes Care Devices Market, United States
3.1 Diabetes Care Devices Market, United States, Revenue ($m), 2018-2033
3.2 Diabetes Care Devices Market, United States, Revenue Mix ($m), 2023
3.3 Diabetes Care Devices Market, United States, Category Contribution by Revenue ($m), 2023
3.4 Diabetes Care Devices Market, United States, Revenue ($m), 2018-2033
3.5 Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
3.6 Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
3.7 Diabetes Care Devices Market, United States, Company Share by Revenue ($m), 2023
3.2 Diabetes Care Devices Market, United States, Revenue Mix ($m), 2023
3.3 Diabetes Care Devices Market, United States, Category Contribution by Revenue ($m), 2023
3.4 Diabetes Care Devices Market, United States, Revenue ($m), 2018-2033
3.5 Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
3.6 Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
3.7 Diabetes Care Devices Market, United States, Company Share by Revenue ($m), 2023
4 Glucose Monitoring Market, United States
4.1 Glucose Monitoring Market, United States, Revenue ($m), 2018-2033
4.1.1 Blood Glucose Meters Market, United States, Revenue ($m), by Segment, 2018-2033
4.2 Glucose Monitoring Market, United States, Volume (Units), 2018-2033
4.2.1 Blood Glucose Meters Market, United States, Volume (Units), by Segment, 2018-2033
4.3 Glucose Monitoring Market, United States, Average Price ($) , 2018-2033
4.4 Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), 2023
4.5 Glucose Monitoring Market, United States, Company Share by Revenue ($m), 2023
4.1.1 Blood Glucose Meters Market, United States, Revenue ($m), by Segment, 2018-2033
4.2 Glucose Monitoring Market, United States, Volume (Units), 2018-2033
4.2.1 Blood Glucose Meters Market, United States, Volume (Units), by Segment, 2018-2033
4.3 Glucose Monitoring Market, United States, Average Price ($) , 2018-2033
4.4 Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), 2023
4.5 Glucose Monitoring Market, United States, Company Share by Revenue ($m), 2023
5 Insulin Delivery Market, United States
5.1 Insulin Delivery Market, United States, Revenue Mix ($m), 2023
5.2 Insulin Delivery Market, United States, Segment Contribution (%), 2023
5.3 Insulin Delivery Market, United States, Revenue ($m), 2018-2033
5.3.1 Insulin Pens Market, United States, Revenue ($m), by Segment, 2018-2033
5.3.2 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2018-2033
5.4 Insulin Delivery Market, United States, Volume (Units), 2018-2033
5.4.1 Insulin Pens Market, United States, Volume (Units), by Segment, 2018-2033
5.4.2 Insulin Pumps Market, United States, Volume (Units), by Segment, 2018-2033
5.5 Insulin Delivery Market, United States, Average Price ($) , 2018-2033
5.6 Insulin Delivery Market, United States, Distribution Share by Revenue ($m), 2023
5.7 Insulin Delivery Market, United States, Company Share by Revenue ($m), 2023
5.2 Insulin Delivery Market, United States, Segment Contribution (%), 2023
5.3 Insulin Delivery Market, United States, Revenue ($m), 2018-2033
5.3.1 Insulin Pens Market, United States, Revenue ($m), by Segment, 2018-2033
5.3.2 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2018-2033
5.4 Insulin Delivery Market, United States, Volume (Units), 2018-2033
5.4.1 Insulin Pens Market, United States, Volume (Units), by Segment, 2018-2033
5.4.2 Insulin Pumps Market, United States, Volume (Units), by Segment, 2018-2033
5.5 Insulin Delivery Market, United States, Average Price ($) , 2018-2033
5.6 Insulin Delivery Market, United States, Distribution Share by Revenue ($m), 2023
5.7 Insulin Delivery Market, United States, Company Share by Revenue ($m), 2023
6 Overview of Key Companies in United States, Diabetes Care Devices Market
6.1 Abbott Laboratories
6.1.1 Company Overview
6.2 DexCom Inc
6.2.1 Company Overview
6.3 Eli Lilly and Co
6.3.1 Company Overview
6.4 Novo Nordisk AS
6.4.1 Company Overview
6.5 Medtronic Plc
6.5.1 Company Overview
6.6 Sanofi
6.6.1 Company Overview
6.7 Insulet Corp
6.7.1 Company Overview
6.8 Tandem Diabetes Care Inc
6.8.1 Company Overview
6.1.1 Company Overview
6.2 DexCom Inc
6.2.1 Company Overview
6.3 Eli Lilly and Co
6.3.1 Company Overview
6.4 Novo Nordisk AS
6.4.1 Company Overview
6.5 Medtronic Plc
6.5.1 Company Overview
6.6 Sanofi
6.6.1 Company Overview
6.7 Insulet Corp
6.7.1 Company Overview
6.8 Tandem Diabetes Care Inc
6.8.1 Company Overview
8 Financial Deals Landscape
8.1 Acquisition
8.1.1 Cardinal Health to Acquire Advanced Diabetes Supply from Court Square Capital Partners for USD1.1 Billion
8.1.2 Searle Denies Rumour to Acquire 51% Stake in Abbott Laboratories
8.1.3 Starboard Value May Acquire Stake in Pfizer for USD1 Billion
8.1.4 Nova Biomedical May Sell Itself
8.1.5 Sumitomo Corporation of Americas (SCOA) Invests in Vast Medical Holdings
8.1.6 Strive Medical Acquires ProMed DME
8.2 Asset Transactions
8.2.1 Trinity Biotech to Acquire Continuous Glucose Monitoring Assets(CGM) from Waveform Technologies for USD21.5 Million
8.3 Debt Offerings
8.3.1 Quest Diagnostics Raises USD400 Million in Public Offering of 4.60% Senior Notes Due 2027
8.3.2 Quest Diagnostics Raises USD600 Million in Public Offering of 4.625% Senior Notes Due 2029
8.3.3 Quest Diagnostics Raises USD850 Million in Public Offering of 5% Senior Notes Due 2034
8.3.4 Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
8.3.5 Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029
8.1.1 Cardinal Health to Acquire Advanced Diabetes Supply from Court Square Capital Partners for USD1.1 Billion
8.1.2 Searle Denies Rumour to Acquire 51% Stake in Abbott Laboratories
8.1.3 Starboard Value May Acquire Stake in Pfizer for USD1 Billion
8.1.4 Nova Biomedical May Sell Itself
8.1.5 Sumitomo Corporation of Americas (SCOA) Invests in Vast Medical Holdings
8.1.6 Strive Medical Acquires ProMed DME
8.2 Asset Transactions
8.2.1 Trinity Biotech to Acquire Continuous Glucose Monitoring Assets(CGM) from Waveform Technologies for USD21.5 Million
8.3 Debt Offerings
8.3.1 Quest Diagnostics Raises USD400 Million in Public Offering of 4.60% Senior Notes Due 2027
8.3.2 Quest Diagnostics Raises USD600 Million in Public Offering of 4.625% Senior Notes Due 2029
8.3.3 Quest Diagnostics Raises USD850 Million in Public Offering of 5% Senior Notes Due 2034
8.3.4 Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
8.3.5 Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029
9 Recent Developments
9.1 Corporate Communications
9.1.1 Oct 17, 2024: AdaptHealth Appoints Diana Nole to Board of Directors
9.1.2 Aug 21, 2024: AGFA HealthCare Announces the UK AGFA HealthCare User Group
9.1.3 Aug 20, 2024: Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
9.1.4 Jul 18, 2024: Eyenuk Appoints Bryan Haardt as Chief Executive Officer
9.1.5 Jul 05, 2024: Afamelanotide Assists DNA Repair Response Following UV Radiation
9.1.6 Jun 03, 2024: Kimball Electronics Appoints New Treasurer
9.1.7 May 31, 2024: Children’s Hospital of Philadelphia Appoints New Chief of Gastroenterology, Hepatology and Nutrition
9.1.8 Apr 11, 2024: Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
9.1.9 Apr 08, 2024: Draper Drives Growth Strategy with Appointment of Carrie George as Chief Financial Officer
9.1.10 Mar 06, 2024: Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
9.1.11 Mar 04, 2024: Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
9.1.12 Mar 04, 2024: Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
9.2 Financial Announcements
9.2.1 Dec 12, 2024: GE HealthCare to Announce Fourth Quarter and Full Year 2024 Results on February 13, 2025
9.2.2 Nov 26, 2024: Embecta Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance
9.2.3 Nov 07, 2024: Nektar Therapeutics Reports Third Quarter 2024 Financial Results
9.2.4 Oct 31, 2024: MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
9.2.5 Oct 23, 2024: Thermo Fisher Scientific Announces Q3 2024 Financial Results
9.2.6 Oct 16, 2024: Lilly Confirms Date and Conference Call for Third-Quarter 2024 Financial Results Announcement
9.2.7 Oct 10, 2024: BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
9.2.8 Oct 01, 2024: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 23, 2024
9.2.9 Sep 26, 2024: Dexcom Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024 at 4:30 p.m. Eastern Time.
9.2.10 Sep 26, 2024: Integer Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024
9.2.11 Jul 25, 2024: Senseonics Holdings Schedules Second Quarter 2024 Earnings Release and Conference Call for August 8, 2024 at 4:30 P.M. Eastern Time
9.2.12 Jul 25, 2024: Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
9.2.13 Jul 08, 2024: Henry Schein to Webcast Second Quarter 2024 Conference Call on Tuesday, August 6, 2024 at 10:00 a.m. ET
9.2.14 Jul 03, 2024: BD to Announce Financial Results for its Third Quarter of Fiscal 2024
9.2.15 Jul 02, 2024: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 24, 2024
9.2.16 Jun 27, 2024: Abbott Hosts Conference Call for Second-Quarter Earnings
9.2.17 Jun 19, 2024: Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024
9.2.18 Jun 04, 2024: Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
9.2.19 May 07, 2024: Kimball Electronics Reports Q3 Results; Company Announces Renewed Strategic Focus, Including Expected Divestiture of the Automation, Test & Measurement Business
9.2.20 May 01, 2024: MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
9.2.21 Apr 16, 2024: Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results
9.2.22 Apr 11, 2024: KORE Reports Fourth Quarter and Full Year 2023 Results; Provides Full-Year 2024 Revenue Guidance of $300 to $305 Million Driven by IoT Connectivity
9.2.23 Apr 04, 2024: BD to Announce Financial Results for its Second Quarter of Fiscal 2024
9.2.24 Apr 03, 2024: Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
9.2.25 Apr 01, 2024: Scientific Industries to Host Full Year 2023 Financial Results Investor Call on April 3, 2024
9.2.26 Mar 19, 2024: Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
9.2.27 Feb 27, 2024: Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call For March 7, 2024 at 8:00 Am ET
9.2.28 Feb 20, 2024: MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
9.2.29 Jan 18, 2024: GE HealthCare to Announce Fourth Quarter and Full Year 2023 Results on February 6, 2024
9.2.30 Jan 05, 2024: BD Announces Webcast of Annual Meeting of Shareholders
9.2.31 Jan 04, 2024: BD to Announce Financial Results for its First Quarter of Fiscal 2024
9.3 Government and Public Interest
9.3.1 Dec 17, 2024: Double Medical Technology Receives 510(K) Clearance For Locking Screw CoCrMo
9.3.2 Oct 04, 2024: Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
9.3.3 Jun 03, 2024: Kimball Electronics Appoints New Treasurer
9.3.4 Jun 01, 2024: Typhoid Fever Vaccine “Tyfim V-I Injection Syringe” Information Regarding Obtaining Manufacturing and Sales Approval
9.3.5 May 27, 2024: Qurient Unveils Q901 ASCO Abstract... Verification of safety and drug response
9.3.6 May 21, 2024: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
9.3.7 May 21, 2024: Henry Schein to Present at Investor Conferences in June 2024
9.3.8 May 07, 2024: Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
9.3.9 Apr 29, 2024: BD to Present at Bank of America Securities Health Care Conference 2024
9.3.10 Apr 24, 2024: Merus Announces Presentation MCLA-129 at the 2024 ASCO Annual Meeting
9.3.11 Apr 22, 2024: Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
9.3.12 Apr 04, 2024: Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
9.3.13 Apr 02, 2024: Johnson & Johnson to Participate in the BofA Securities Health Care Conference
9.3.14 Mar 04, 2024: Biden-Harris Administration Receives Counteroffers from Drug Companies as Part of Ongoing Negotiations to Lower Drug Prices
9.3.15 Feb 23, 2024: Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
9.3.16 Feb 15, 2024: BD to Present at Investor Healthcare Conferences
9.3.17 Feb 14, 2024: GE HealthCare Management to Present at Upcoming Investor Conferences
9.3.18 Feb 14, 2024: Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
9.3.19 Feb 13, 2024: Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
9.3.20 Jan 26, 2024: Gm Dos Reis Industria E Comerico Receives FDA 510(k) Clearance for Quick - Radius Disposable Set
9.3.21 Jan 03, 2024: Henry Schein to Present at J.P. Morgan’s Healthcare Investor Conference
9.4 Legal And Regulatory
9.4.1 Dec 23, 2024: Abbott Agrees to Global Continuous Glucose Monitoring Litigation Settlement with Dexcom
9.4.2 Dec 18, 2024: Positive Results Advance Peanut Tablet to Phase II Development
9.4.3 Dec 04, 2024: Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
9.4.4 Nov 12, 2024: ViiV Healthcare shares results from trial of Dovato and three-drug therapy for HIV
9.4.5 Sep 11, 2024: Iantrek Announces Publication of Results of its Bio-interventional Uveoscleral Outflow Technology in Patients with Open-Angle Glaucoma
9.4.6 Aug 14, 2024: Enrollment Completed in Phase 3 Clinical Study of Disitamab Vedotin Combined with PD-1 Inhibitor as First-Line Treatment for Urothelial Carcinoma
9.4.7 May 14, 2024: Valcare Medical Announces Enrollment of First Two Patients in AMEND TS EU Pilot Study
9.4.8 Feb 29, 2024: Megadyne Reiterates Intended Use Population Change for Megadyne Mega Soft Universal and Universal Plus Patient Return Electrodes
9.5 Other Significant Developments
9.5.1 Nov 19, 2024: Pii Expands Prefilled Syringe Services with $3.6M Investment in Capacity and Technology Upgrades
9.5.2 Nov 19, 2024: Owen Mumford Signs Safety Phlebotomy and Specimen Collection Products Agreement With Premier
9.5.3 Nov 18, 2024: Abbott Opens State-Of-The-Art Global Manufacturing Facility in Kilkenny, Ireland
9.5.4 Nov 01, 2024: Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November
9.5.5 Sep 27, 2024: Diabetic Exchange USA Introduces a Better Way to Sell Diabetic Supplies
9.5.6 Aug 26, 2024: Ochsner Digital Medicine teams up with AmeriHealth Caritas Louisiana to improve treatment of hypertension, Type 2 diabetes
9.5.7 Jul 29, 2024: Genpact Supports embecta''s Spin-Off into an Independent Diabetes Care Company
9.5.8 Jul 16, 2024: Dario Expands GLP-1 Solution Client Base with New Employer Contract
9.5.9 Jun 06, 2024: LIFE Sterilization protocol ready for the production line
9.5.10 May 20, 2024: Vanderbilt Researchers Receive $2 Million ARPA-H Contract to Improve Software Security in Medical Devices
9.5.11 Feb 12, 2024: Tyber Medical Acquires FDA Clearance for Proximal Tibia Plating System
9.5.12 Jan 19, 2024: Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland
9.5.13 Jan 16, 2024: New Initiative Focuses on Oral Health Clinicians in Prevention and Early Detection of Heart Disease
9.5.14 Jan 11, 2024: Veri Releases New Metabolic Health Program
9.6 Product News
9.6.1 Dec 04, 2024: New Study Shows Active Participation in iHealth's Unified Care Program Results in Significant Health Improvement for Patients with Stage 2 Hypertension
9.6.2 Nov 13, 2024: Validic Advances Diabetes Care with Seamless Cgm Integration into EHR Workflows
9.6.3 Nov 13, 2024: Healthcare Startup Focused on High-Risk Prenatal Care Launches Out of Stealth with New Platform to Modernize Gestational Diabetes Management
9.6.4 Oct 04, 2024: BD Showcases Latest Drug Delivery Innovations at CPhI Milan 2024
9.6.5 Oct 02, 2024: Rice’s Biotech Launch Pad to Lead Commercialization of Bioelectrical Implant Treatment for Obesity, Type 2 Diabetes
9.6.6 Oct 01, 2024: Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
9.6.7 Sep 25, 2024: Applied Science Releases New Advanced Technologies to Improve Care for People Living With Diabetes in Rural and Under-Served Communities
9.6.8 Aug 26, 2024: FDA Clears First Device To Enable Automated Insulin Dosing For Individuals With Type 2 Diabetes
9.6.9 Aug 13, 2024: New UH Study Targets Early Signs of Vision Loss in Diabetic Patients
9.6.10 Jun 24, 2024: American Diabetes Association Showcases Innovations and Guidance for Early Risk Monitoring of Type 1 Diabetes
9.6.11 Jun 24, 2024: Embecta-Sponsored Abstracts Presented at American Diabetes Association’s 84th Scientific Sessions Highlight Unmet Need for Patch Pumps With 300U Insulin Reservoir
9.6.12 Jun 10, 2024: Health for Mankind Company Launches DIABIMETRICS, A Bold Step Towards Revolutionizing Diabetes Management and Eliminating Health Disparities
9.6.13 May 21, 2024: YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality
9.6.14 May 02, 2024: Adding AI to Artificial Pancreas Enhances Efficiency, Study Finds
9.6.15 Apr 05, 2024: Know Labs to Present Clinical Research at the 2024 American Physiology Summit
9.6.16 Mar 06, 2024: embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes
9.6.17 Mar 06, 2024: Real-World Data Show Abbott's FreeStyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes
9.6.18 Mar 06, 2024: AI Can Speed Design of Health Software
9.6.19 Jan 26, 2024: New Study: Biomarkers That Improve Prediction of Cardiovascular Disease in Type 2 Diabetes
9.6.20 Jan 24, 2024: Modular Medical Announces Issuance of New US Patent
9.6.21 Jan 23, 2024: Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
9.6.22 Jan 04, 2024: Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect
9.7 Research And Development
9.7.1 Feb 12, 2024: Health Canada Approves Keytruda in Combination With Trastuzumab and Chemotherapy, as a First-Line Treatment for Metastatic HER2-Positive Gastric
9.8 Strategy And Business Planning
9.8.1 Dec 04, 2024: Avant Technologies Partner, Ainnova, Signs Pilot Program With Roche to Combat Diabetic Retinopathy
9.8.2 Nov 18, 2024: Abbott Launches Global Manufacturing Facility in Kilkenny, Ireland
9.8.3 Nov 18, 2024: Abbott Opens State-Of-The-Art Global Manufacturing Facility in Kilkenny, Ireland
9.8.4 Oct 01, 2024: Glytec and Ardent Partner to Boost Diabetes and Insulin Management Nationwide
9.8.5 Sep 24, 2024: Rimidi Increases Customer Base by 400%, Expands Partnerships and Services in 2024 to Support Future Growth
9.8.6 Sep 14, 2024: RYBREVANT (Amivantamab) Plus Chemotherapy Show 49 Percent Overall Response Rate in Metastatic Colorectal Cancer
9.8.7 Aug 26, 2024: Ochsner Digital Medicine teams up with AmeriHealth Caritas Louisiana to improve treatment of hypertension, Type 2 diabetes
9.8.8 May 14, 2024: Glytec and University Hospitals (UH) Forge Strategic Partnership
9.8.9 Apr 18, 2024: Glytec Announces Support for Landmark New CMS Measures to Improve Diabetes Reporting
9.8.10 Mar 08, 2024: New Data Published by Omada Health Demonstrates the Impact of Coupling GLP-1s and Behavior Change Programming
9.8.11 Feb 08, 2024: Ubiquitech Software Unveils Groundbreaking Lifestyle Video Marketing Initiative for Innovative Outcomes Driving Rapid Company Growth
9.8.12 Jan 17, 2024: Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
9.8.13 Jan 16, 2024: Orbis International and Nidek Join Forces to Scale Up Artificial Intelligence Eye Screenings in Vietnam
9.1.1 Oct 17, 2024: AdaptHealth Appoints Diana Nole to Board of Directors
9.1.2 Aug 21, 2024: AGFA HealthCare Announces the UK AGFA HealthCare User Group
9.1.3 Aug 20, 2024: Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
9.1.4 Jul 18, 2024: Eyenuk Appoints Bryan Haardt as Chief Executive Officer
9.1.5 Jul 05, 2024: Afamelanotide Assists DNA Repair Response Following UV Radiation
9.1.6 Jun 03, 2024: Kimball Electronics Appoints New Treasurer
9.1.7 May 31, 2024: Children’s Hospital of Philadelphia Appoints New Chief of Gastroenterology, Hepatology and Nutrition
9.1.8 Apr 11, 2024: Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
9.1.9 Apr 08, 2024: Draper Drives Growth Strategy with Appointment of Carrie George as Chief Financial Officer
9.1.10 Mar 06, 2024: Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
9.1.11 Mar 04, 2024: Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
9.1.12 Mar 04, 2024: Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
9.2 Financial Announcements
9.2.1 Dec 12, 2024: GE HealthCare to Announce Fourth Quarter and Full Year 2024 Results on February 13, 2025
9.2.2 Nov 26, 2024: Embecta Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance
9.2.3 Nov 07, 2024: Nektar Therapeutics Reports Third Quarter 2024 Financial Results
9.2.4 Oct 31, 2024: MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
9.2.5 Oct 23, 2024: Thermo Fisher Scientific Announces Q3 2024 Financial Results
9.2.6 Oct 16, 2024: Lilly Confirms Date and Conference Call for Third-Quarter 2024 Financial Results Announcement
9.2.7 Oct 10, 2024: BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
9.2.8 Oct 01, 2024: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 23, 2024
9.2.9 Sep 26, 2024: Dexcom Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024 at 4:30 p.m. Eastern Time.
9.2.10 Sep 26, 2024: Integer Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024
9.2.11 Jul 25, 2024: Senseonics Holdings Schedules Second Quarter 2024 Earnings Release and Conference Call for August 8, 2024 at 4:30 P.M. Eastern Time
9.2.12 Jul 25, 2024: Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
9.2.13 Jul 08, 2024: Henry Schein to Webcast Second Quarter 2024 Conference Call on Tuesday, August 6, 2024 at 10:00 a.m. ET
9.2.14 Jul 03, 2024: BD to Announce Financial Results for its Third Quarter of Fiscal 2024
9.2.15 Jul 02, 2024: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 24, 2024
9.2.16 Jun 27, 2024: Abbott Hosts Conference Call for Second-Quarter Earnings
9.2.17 Jun 19, 2024: Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024
9.2.18 Jun 04, 2024: Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
9.2.19 May 07, 2024: Kimball Electronics Reports Q3 Results; Company Announces Renewed Strategic Focus, Including Expected Divestiture of the Automation, Test & Measurement Business
9.2.20 May 01, 2024: MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
9.2.21 Apr 16, 2024: Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results
9.2.22 Apr 11, 2024: KORE Reports Fourth Quarter and Full Year 2023 Results; Provides Full-Year 2024 Revenue Guidance of $300 to $305 Million Driven by IoT Connectivity
9.2.23 Apr 04, 2024: BD to Announce Financial Results for its Second Quarter of Fiscal 2024
9.2.24 Apr 03, 2024: Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
9.2.25 Apr 01, 2024: Scientific Industries to Host Full Year 2023 Financial Results Investor Call on April 3, 2024
9.2.26 Mar 19, 2024: Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
9.2.27 Feb 27, 2024: Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call For March 7, 2024 at 8:00 Am ET
9.2.28 Feb 20, 2024: MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
9.2.29 Jan 18, 2024: GE HealthCare to Announce Fourth Quarter and Full Year 2023 Results on February 6, 2024
9.2.30 Jan 05, 2024: BD Announces Webcast of Annual Meeting of Shareholders
9.2.31 Jan 04, 2024: BD to Announce Financial Results for its First Quarter of Fiscal 2024
9.3 Government and Public Interest
9.3.1 Dec 17, 2024: Double Medical Technology Receives 510(K) Clearance For Locking Screw CoCrMo
9.3.2 Oct 04, 2024: Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
9.3.3 Jun 03, 2024: Kimball Electronics Appoints New Treasurer
9.3.4 Jun 01, 2024: Typhoid Fever Vaccine “Tyfim V-I Injection Syringe” Information Regarding Obtaining Manufacturing and Sales Approval
9.3.5 May 27, 2024: Qurient Unveils Q901 ASCO Abstract... Verification of safety and drug response
9.3.6 May 21, 2024: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
9.3.7 May 21, 2024: Henry Schein to Present at Investor Conferences in June 2024
9.3.8 May 07, 2024: Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
9.3.9 Apr 29, 2024: BD to Present at Bank of America Securities Health Care Conference 2024
9.3.10 Apr 24, 2024: Merus Announces Presentation MCLA-129 at the 2024 ASCO Annual Meeting
9.3.11 Apr 22, 2024: Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
9.3.12 Apr 04, 2024: Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
9.3.13 Apr 02, 2024: Johnson & Johnson to Participate in the BofA Securities Health Care Conference
9.3.14 Mar 04, 2024: Biden-Harris Administration Receives Counteroffers from Drug Companies as Part of Ongoing Negotiations to Lower Drug Prices
9.3.15 Feb 23, 2024: Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
9.3.16 Feb 15, 2024: BD to Present at Investor Healthcare Conferences
9.3.17 Feb 14, 2024: GE HealthCare Management to Present at Upcoming Investor Conferences
9.3.18 Feb 14, 2024: Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
9.3.19 Feb 13, 2024: Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
9.3.20 Jan 26, 2024: Gm Dos Reis Industria E Comerico Receives FDA 510(k) Clearance for Quick - Radius Disposable Set
9.3.21 Jan 03, 2024: Henry Schein to Present at J.P. Morgan’s Healthcare Investor Conference
9.4 Legal And Regulatory
9.4.1 Dec 23, 2024: Abbott Agrees to Global Continuous Glucose Monitoring Litigation Settlement with Dexcom
9.4.2 Dec 18, 2024: Positive Results Advance Peanut Tablet to Phase II Development
9.4.3 Dec 04, 2024: Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
9.4.4 Nov 12, 2024: ViiV Healthcare shares results from trial of Dovato and three-drug therapy for HIV
9.4.5 Sep 11, 2024: Iantrek Announces Publication of Results of its Bio-interventional Uveoscleral Outflow Technology in Patients with Open-Angle Glaucoma
9.4.6 Aug 14, 2024: Enrollment Completed in Phase 3 Clinical Study of Disitamab Vedotin Combined with PD-1 Inhibitor as First-Line Treatment for Urothelial Carcinoma
9.4.7 May 14, 2024: Valcare Medical Announces Enrollment of First Two Patients in AMEND TS EU Pilot Study
9.4.8 Feb 29, 2024: Megadyne Reiterates Intended Use Population Change for Megadyne Mega Soft Universal and Universal Plus Patient Return Electrodes
9.5 Other Significant Developments
9.5.1 Nov 19, 2024: Pii Expands Prefilled Syringe Services with $3.6M Investment in Capacity and Technology Upgrades
9.5.2 Nov 19, 2024: Owen Mumford Signs Safety Phlebotomy and Specimen Collection Products Agreement With Premier
9.5.3 Nov 18, 2024: Abbott Opens State-Of-The-Art Global Manufacturing Facility in Kilkenny, Ireland
9.5.4 Nov 01, 2024: Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November
9.5.5 Sep 27, 2024: Diabetic Exchange USA Introduces a Better Way to Sell Diabetic Supplies
9.5.6 Aug 26, 2024: Ochsner Digital Medicine teams up with AmeriHealth Caritas Louisiana to improve treatment of hypertension, Type 2 diabetes
9.5.7 Jul 29, 2024: Genpact Supports embecta''s Spin-Off into an Independent Diabetes Care Company
9.5.8 Jul 16, 2024: Dario Expands GLP-1 Solution Client Base with New Employer Contract
9.5.9 Jun 06, 2024: LIFE Sterilization protocol ready for the production line
9.5.10 May 20, 2024: Vanderbilt Researchers Receive $2 Million ARPA-H Contract to Improve Software Security in Medical Devices
9.5.11 Feb 12, 2024: Tyber Medical Acquires FDA Clearance for Proximal Tibia Plating System
9.5.12 Jan 19, 2024: Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland
9.5.13 Jan 16, 2024: New Initiative Focuses on Oral Health Clinicians in Prevention and Early Detection of Heart Disease
9.5.14 Jan 11, 2024: Veri Releases New Metabolic Health Program
9.6 Product News
9.6.1 Dec 04, 2024: New Study Shows Active Participation in iHealth's Unified Care Program Results in Significant Health Improvement for Patients with Stage 2 Hypertension
9.6.2 Nov 13, 2024: Validic Advances Diabetes Care with Seamless Cgm Integration into EHR Workflows
9.6.3 Nov 13, 2024: Healthcare Startup Focused on High-Risk Prenatal Care Launches Out of Stealth with New Platform to Modernize Gestational Diabetes Management
9.6.4 Oct 04, 2024: BD Showcases Latest Drug Delivery Innovations at CPhI Milan 2024
9.6.5 Oct 02, 2024: Rice’s Biotech Launch Pad to Lead Commercialization of Bioelectrical Implant Treatment for Obesity, Type 2 Diabetes
9.6.6 Oct 01, 2024: Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
9.6.7 Sep 25, 2024: Applied Science Releases New Advanced Technologies to Improve Care for People Living With Diabetes in Rural and Under-Served Communities
9.6.8 Aug 26, 2024: FDA Clears First Device To Enable Automated Insulin Dosing For Individuals With Type 2 Diabetes
9.6.9 Aug 13, 2024: New UH Study Targets Early Signs of Vision Loss in Diabetic Patients
9.6.10 Jun 24, 2024: American Diabetes Association Showcases Innovations and Guidance for Early Risk Monitoring of Type 1 Diabetes
9.6.11 Jun 24, 2024: Embecta-Sponsored Abstracts Presented at American Diabetes Association’s 84th Scientific Sessions Highlight Unmet Need for Patch Pumps With 300U Insulin Reservoir
9.6.12 Jun 10, 2024: Health for Mankind Company Launches DIABIMETRICS, A Bold Step Towards Revolutionizing Diabetes Management and Eliminating Health Disparities
9.6.13 May 21, 2024: YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality
9.6.14 May 02, 2024: Adding AI to Artificial Pancreas Enhances Efficiency, Study Finds
9.6.15 Apr 05, 2024: Know Labs to Present Clinical Research at the 2024 American Physiology Summit
9.6.16 Mar 06, 2024: embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes
9.6.17 Mar 06, 2024: Real-World Data Show Abbott's FreeStyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes
9.6.18 Mar 06, 2024: AI Can Speed Design of Health Software
9.6.19 Jan 26, 2024: New Study: Biomarkers That Improve Prediction of Cardiovascular Disease in Type 2 Diabetes
9.6.20 Jan 24, 2024: Modular Medical Announces Issuance of New US Patent
9.6.21 Jan 23, 2024: Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
9.6.22 Jan 04, 2024: Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect
9.7 Research And Development
9.7.1 Feb 12, 2024: Health Canada Approves Keytruda in Combination With Trastuzumab and Chemotherapy, as a First-Line Treatment for Metastatic HER2-Positive Gastric
9.8 Strategy And Business Planning
9.8.1 Dec 04, 2024: Avant Technologies Partner, Ainnova, Signs Pilot Program With Roche to Combat Diabetic Retinopathy
9.8.2 Nov 18, 2024: Abbott Launches Global Manufacturing Facility in Kilkenny, Ireland
9.8.3 Nov 18, 2024: Abbott Opens State-Of-The-Art Global Manufacturing Facility in Kilkenny, Ireland
9.8.4 Oct 01, 2024: Glytec and Ardent Partner to Boost Diabetes and Insulin Management Nationwide
9.8.5 Sep 24, 2024: Rimidi Increases Customer Base by 400%, Expands Partnerships and Services in 2024 to Support Future Growth
9.8.6 Sep 14, 2024: RYBREVANT (Amivantamab) Plus Chemotherapy Show 49 Percent Overall Response Rate in Metastatic Colorectal Cancer
9.8.7 Aug 26, 2024: Ochsner Digital Medicine teams up with AmeriHealth Caritas Louisiana to improve treatment of hypertension, Type 2 diabetes
9.8.8 May 14, 2024: Glytec and University Hospitals (UH) Forge Strategic Partnership
9.8.9 Apr 18, 2024: Glytec Announces Support for Landmark New CMS Measures to Improve Diabetes Reporting
9.8.10 Mar 08, 2024: New Data Published by Omada Health Demonstrates the Impact of Coupling GLP-1s and Behavior Change Programming
9.8.11 Feb 08, 2024: Ubiquitech Software Unveils Groundbreaking Lifestyle Video Marketing Initiative for Innovative Outcomes Driving Rapid Company Growth
9.8.12 Jan 17, 2024: Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
9.8.13 Jan 16, 2024: Orbis International and Nidek Join Forces to Scale Up Artificial Intelligence Eye Screenings in Vietnam
10 Appendix
10.1 Research Methodology
10.1.1 Coverage
10.1.2 Secondary Research
10.1.3 Primary Research
10.1.4 Market Modeling and Forecasting
10.1.5 Company Share Analysis
10.1.6 Distribution Share Analysis
10.1.7 Benchmarking
10.2 The Publisher's Consulting
10.3 Contact the Publisher
10.4 Disclaimer
10.1.1 Coverage
10.1.2 Secondary Research
10.1.3 Primary Research
10.1.4 Market Modeling and Forecasting
10.1.5 Company Share Analysis
10.1.6 Distribution Share Analysis
10.1.7 Benchmarking
10.2 The Publisher's Consulting
10.3 Contact the Publisher
10.4 Disclaimer
List of Tables
Table 1: Diabetes Care Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 2: Diabetes Care Devices Market, United States, Category Contribution by Revenue ($m), 2023
Table 3: Diabetes Care Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 4: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Table 5: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Table 6: Diabetes Care Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 7: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 8: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 9: Glucose Monitoring Market, United States, Volume (Units), 2018-2033
Table 10: Blood Glucose Meters Market, United States, Volume (Units), 2018-2033
Table 11: Glucose Monitoring Market, United States, Average Price ($), 2018-2033
Table 12: Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), USD Constant, 2023
Table 13: Glucose Monitoring Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 14: Insulin Delivery Market, United States, Segment Contribution (%), 2023
Table 15: Insulin Delivery Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 16: Insulin Pens Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 17: Insulin Pumps Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 18: Insulin Delivery Market, United States, Volume (Units), 2018-2033
Table 19: Insulin Pens Market, United States, Volume (Units), 2018-2033
Table 20: Insulin Pumps Market, United States, Volume (Units), 2018-2033
Table 21: Insulin Delivery Market, United States, Average Price ($), 2018-2033
Table 22: Insulin Delivery Market, United States, Distribution Share by Revenue ($m), USD Constant, 2023
Table 23: Insulin Delivery Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 24: Diabetes Care Devices Market Pipeline Products
Table 25: Cardinal Health to Acquire Advanced Diabetes Supply from Court Square Capital Partners for USD1.1 Billion
Table 26: Searle Denies Rumour to Acquire 51% Stake in Abbott Laboratories
Table 27: Starboard Value May Acquire Stake in Pfizer for USD1 Billion
Table 28: Nova Biomedical May Sell Itself
Table 29: Sumitomo Corporation of Americas (SCOA) Invests in Vast Medical Holdings
Table 30: Strive Medical Acquires ProMed DME
Table 31: Trinity Biotech to Acquire Continuous Glucose Monitoring Assets(CGM) from Waveform Technologies for USD21.5 Million
Table 32: Quest Diagnostics Raises USD400 Million in Public Offering of 4.60% Senior Notes Due 2027
Table 33: Quest Diagnostics Raises USD600 Million in Public Offering of 4.625% Senior Notes Due 2029
Table 34: Quest Diagnostics Raises USD850 Million in Public Offering of 5% Senior Notes Due 2034
Table 35: Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
Table 36: Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029
Table 2: Diabetes Care Devices Market, United States, Category Contribution by Revenue ($m), 2023
Table 3: Diabetes Care Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 4: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Table 5: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Table 6: Diabetes Care Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 7: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 8: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 9: Glucose Monitoring Market, United States, Volume (Units), 2018-2033
Table 10: Blood Glucose Meters Market, United States, Volume (Units), 2018-2033
Table 11: Glucose Monitoring Market, United States, Average Price ($), 2018-2033
Table 12: Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), USD Constant, 2023
Table 13: Glucose Monitoring Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 14: Insulin Delivery Market, United States, Segment Contribution (%), 2023
Table 15: Insulin Delivery Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 16: Insulin Pens Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 17: Insulin Pumps Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 18: Insulin Delivery Market, United States, Volume (Units), 2018-2033
Table 19: Insulin Pens Market, United States, Volume (Units), 2018-2033
Table 20: Insulin Pumps Market, United States, Volume (Units), 2018-2033
Table 21: Insulin Delivery Market, United States, Average Price ($), 2018-2033
Table 22: Insulin Delivery Market, United States, Distribution Share by Revenue ($m), USD Constant, 2023
Table 23: Insulin Delivery Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 24: Diabetes Care Devices Market Pipeline Products
Table 25: Cardinal Health to Acquire Advanced Diabetes Supply from Court Square Capital Partners for USD1.1 Billion
Table 26: Searle Denies Rumour to Acquire 51% Stake in Abbott Laboratories
Table 27: Starboard Value May Acquire Stake in Pfizer for USD1 Billion
Table 28: Nova Biomedical May Sell Itself
Table 29: Sumitomo Corporation of Americas (SCOA) Invests in Vast Medical Holdings
Table 30: Strive Medical Acquires ProMed DME
Table 31: Trinity Biotech to Acquire Continuous Glucose Monitoring Assets(CGM) from Waveform Technologies for USD21.5 Million
Table 32: Quest Diagnostics Raises USD400 Million in Public Offering of 4.60% Senior Notes Due 2027
Table 33: Quest Diagnostics Raises USD600 Million in Public Offering of 4.625% Senior Notes Due 2029
Table 34: Quest Diagnostics Raises USD850 Million in Public Offering of 5% Senior Notes Due 2034
Table 35: Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
Table 36: Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029
List of Figures
Figure 1: Diabetes Care Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 2: Diabetes Care Devices Market, United States, Revenue Mix ($m), 2023
Figure 3: Diabetes Care Devices Market, United States, Category Contribution (%), 2023
Figure 4: Diabetes Care Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 5: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Figure 6: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Figure 7: Diabetes Care Devices Market, United States, Company Share (%) 2023
Figure 8: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 9: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 10: Glucose Monitoring Market, United States, Volume (Units), 2018-2033
Figure 11: Blood Glucose Meters Market, United States, Volume (Units), 2018-2033
Figure 12: Glucose Monitoring Market, United States, Company Share (%) 2023
Figure 13: Insulin Delivery Market, United States, Revenue Mix ($m), 2023
Figure 14: Insulin Delivery Market, United States, Segment Contribution (%), 2023
Figure 15: Insulin Delivery Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 16: Insulin Pens Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 17: Insulin Pumps Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 18: Insulin Delivery Market, United States, Volume (Units), 2018-2033
Figure 19: Insulin Pens Market, United States, Volume (Units), 2018-2033
Figure 20: Insulin Pumps Market, United States, Volume (Units), 2018-2033
Figure 21: Insulin Delivery Market, United States, Company Share (%) 2023
Figure 2: Diabetes Care Devices Market, United States, Revenue Mix ($m), 2023
Figure 3: Diabetes Care Devices Market, United States, Category Contribution (%), 2023
Figure 4: Diabetes Care Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 5: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Figure 6: Diabetes Care Devices Market, United States, Volume (Units), 2018-2033
Figure 7: Diabetes Care Devices Market, United States, Company Share (%) 2023
Figure 8: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 9: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 10: Glucose Monitoring Market, United States, Volume (Units), 2018-2033
Figure 11: Blood Glucose Meters Market, United States, Volume (Units), 2018-2033
Figure 12: Glucose Monitoring Market, United States, Company Share (%) 2023
Figure 13: Insulin Delivery Market, United States, Revenue Mix ($m), 2023
Figure 14: Insulin Delivery Market, United States, Segment Contribution (%), 2023
Figure 15: Insulin Delivery Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 16: Insulin Pens Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 17: Insulin Pumps Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 18: Insulin Delivery Market, United States, Volume (Units), 2018-2033
Figure 19: Insulin Pens Market, United States, Volume (Units), 2018-2033
Figure 20: Insulin Pumps Market, United States, Volume (Units), 2018-2033
Figure 21: Insulin Delivery Market, United States, Company Share (%) 2023
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eli Lilly and Co
- Novo Nordisk AS
- Medtronic Plc
- Abbott Laboratories
- Sanofi
- DexCom Inc
- Insulet Corp
- Tandem Diabetes Care Inc
